Choi P M, Weinstein I B
Comprehensive Cancer Center, Columbia University, New York, NY 10032.
Biochem Biophys Res Commun. 1991 Dec 16;181(2):809-17. doi: 10.1016/0006-291x(91)91262-b.
To examine whether protein kinase C (PKC) plays a role in mediating growth inhibitory effects of hexamethylene bisacetamide (HMBA) we compared a control H29 colon cancer cell line to a derivative, HT29-PKC7, that overexpresses high levels of PKC beta 1. We found that although HMBA markedly inhibited the growth of the control cells, no inhibition was seen with the HT29-PKC7 cells. On the other hand the tumor promoter 12-0-tetradecanoyl-phorbol-13 acetate inhibited the growth of HT29-PKC7 cells, but no inhibition was seen with the control cells. Maximum inhibition of the growth of both cell lines was obtained by combined treatment with HMBA and TPA. These results may be relevant to the use of HMBA in combination with other agents in the therapy of specific cancers.
为了研究蛋白激酶C（PKC）是否在介导六甲撑双乙酰胺（HMBA）的生长抑制作用中发挥作用，我们将对照H29结肠癌细胞系与一种衍生物HT29 - PKC7进行了比较，该衍生物过表达高水平的PKCβ1。我们发现，虽然HMBA显著抑制对照细胞的生长，但HT29 - PKC7细胞未见抑制作用。另一方面，肿瘤促进剂12 - O - 十四烷酰佛波醇 - 13 - 乙酸酯抑制HT29 - PKC7细胞的生长，但对照细胞未见抑制作用。通过HMBA和TPA联合处理获得了两种细胞系生长的最大抑制效果。这些结果可能与HMBA与其他药物联合用于特定癌症的治疗有关。
